These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 22573668)

  • 21. White Adipose Tissue Browning in the R6/2 Mouse Model of Huntington's Disease.
    McCourt AC; Jakobsson L; Larsson S; Holm C; Piel S; Elmér E; Björkqvist M
    PLoS One; 2016; 11(8):e0159870. PubMed ID: 27486903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients.
    Seo H; Kim W; Isacson O
    Hum Mol Genet; 2008 Oct; 17(20):3144-53. PubMed ID: 18640989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Spatiotemporal mapping of brain atrophy in mouse models of Huntington's disease using longitudinal in vivo magnetic resonance imaging.
    Aggarwal M; Duan W; Hou Z; Rakesh N; Peng Q; Ross CA; Miller MI; Mori S; Zhang J
    Neuroimage; 2012 May; 60(4):2086-95. PubMed ID: 22342677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signature changes in ubiquilin expression in the R6/2 mouse model of Huntington's disease.
    Safren N; Chang L; Dziki KM; Monteiro MJ
    Brain Res; 2015 Feb; 1597():37-46. PubMed ID: 25511991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington's Disease: Preclinical Evidence with the p75
    Simmons DA; Mills BD; Butler Iii RR; Kuan J; McHugh TLM; Akers C; Zhou J; Syriani W; Grouban M; Zeineh M; Longo FM
    Neurotherapeutics; 2021 Apr; 18(2):1039-1063. PubMed ID: 33786806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of magnetic resonance imaging for anatomical phenotyping of the R6/2 mouse model of Huntington's disease.
    Sawiak SJ; Wood NI; Williams GB; Morton AJ; Carpenter TA
    Neurobiol Dis; 2009 Jan; 33(1):12-9. PubMed ID: 18930823
    [TBL] [Abstract][Full Text] [Related]  

  • 28. M2 Cortex Circuitry and Sensory-Induced Behavioral Alterations in Huntington's Disease: Role of Superior Colliculus.
    Conde-Berriozabal S; García-Gilabert L; García-García E; Sitjà-Roqueta L; López-Gil X; Muñoz-Moreno E; Boutagouga Boudjadja M; Soria G; Rodríguez MJ; Alberch J; Masana M
    J Neurosci; 2023 May; 43(18):3379-3390. PubMed ID: 37001992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wheel running from a juvenile age delays onset of specific motor deficits but does not alter protein aggregate density in a mouse model of Huntington's disease.
    van Dellen A; Cordery PM; Spires TL; Blakemore C; Hannan AJ
    BMC Neurosci; 2008 Apr; 9():34. PubMed ID: 18380890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
    Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
    Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain Cholesterol Synthesis and Metabolism is Progressively Disturbed in the R6/1 Mouse Model of Huntington's Disease: A Targeted GC-MS/MS Sterol Analysis.
    Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
    J Huntingtons Dis; 2015; 4(4):305-18. PubMed ID: 26639223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease.
    Zacharoff L; Tkac I; Song Q; Tang C; Bolan PJ; Mangia S; Henry PG; Li T; Dubinsky JM
    J Cereb Blood Flow Metab; 2012 Mar; 32(3):502-14. PubMed ID: 22044866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.
    Hebb AL; Robertson HA; Denovan-Wright EM
    Neuroscience; 2004; 123(4):967-81. PubMed ID: 14751289
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.
    Sathasivam K; Woodman B; Mahal A; Bertaux F; Wanker EE; Shima DT; Bates GP
    Hum Mol Genet; 2001 Oct; 10(21):2425-35. PubMed ID: 11689489
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.
    Hansson O; Nylandsted J; Castilho RF; Leist M; Jäättelä M; Brundin P
    Brain Res; 2003 Apr; 970(1-2):47-57. PubMed ID: 12706247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in striatal activity and functional connectivity in a mouse model of Huntington's disease.
    Cabanas M; Bassil F; Mons N; Garret M; Cho YH
    PLoS One; 2017; 12(9):e0184580. PubMed ID: 28934250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
    Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
    J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brain pericyte activation occurs early in Huntington's disease.
    Padel T; Roth M; Gaceb A; Li JY; Björkqvist M; Paul G
    Exp Neurol; 2018 Jul; 305():139-150. PubMed ID: 29630897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease.
    Cummings DM; André VM; Uzgil BO; Gee SM; Fisher YE; Cepeda C; Levine MS
    J Neurosci; 2009 Aug; 29(33):10371-86. PubMed ID: 19692612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Longitudinal characterization of brain atrophy of a Huntington's disease mouse model by automated morphological analyses of magnetic resonance images.
    Zhang J; Peng Q; Li Q; Jahanshad N; Hou Z; Jiang M; Masuda N; Langbehn DR; Miller MI; Mori S; Ross CA; Duan W
    Neuroimage; 2010 Feb; 49(3):2340-51. PubMed ID: 19850133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.